

such as sign language interpretation or other reasonable accommodations, must notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Mental Health Council.

*Date:* May 16–17, 2023.

*Open:* May 16, 2023, 12:00 p.m. to 4:30 p.m.

*Agenda:* Presentation of the NIMH Director's Report and discussion of NIMH programs.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Room 160, Bethesda, MD 20892.

*Closed:* May 17, 2023, 12:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications and/or contract proposals.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Room 160, Bethesda, MD 20892.

*Contact Person:* Tracy L. Waldeck, Ph.D., Director, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Bethesda, MD 20892, (301) 480-6833, [tracy.waldeck@nih.gov](mailto:tracy.waldeck@nih.gov).

Any member of the public interested in presenting oral comments to the committee must notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice at least 10 days in advance of the meeting. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about->

[nih/visitor-information/campus-access-security](https://www.nih.gov/about-) for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/index.shtml](http://www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/index.shtml), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: April 19, 2023.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-08631 Filed 4-24-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Division of Intramural Research Board of Scientific Counselors, NIAID.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Allergy and Infectious Diseases, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Division of Intramural Research Board of Scientific Counselors, NIAID.

*Date:* June 12–14, 2023.

*Time:* 7:45 a.m. to 10:55 a.m.

*Agenda:* To review and evaluate personnel qualifications and performance, and competence of individual investigators.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Conference Room 1227/1233, 50 Center Drive, Bethesda, MD 20892.

*Contact Person:* Laurie Lewallen, Division of Intramural Research Program Support

Staff, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 33, Room 1N24, 33 North Drive, Bethesda, MD 20892, 301-761-6362, [Laurie.Lewallen@nih.gov](mailto:Laurie.Lewallen@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 19, 2023.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-08626 Filed 4-24-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

#### **FOR FURTHER INFORMATION CONTACT:**

Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852 by contacting Dr. Benjamin Hurley at 240-669-5092 or [benjamin.hurley@nih.gov](mailto:benjamin.hurley@nih.gov). A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

#### **SUPPLEMENTARY INFORMATION:**

Technology description follows:

#### **Engineered Cell-Penetrating Monoclonal Antibody for Universal Influenza Immunotherapy**

##### *Description of Technology:*

Influenza remains a burden on public health, as current treatments of viral infections remain ineffective due to frequent virus mutations. Many current influenza treatments rely on targeting surface viral glycoproteins. Unfortunately, these glycoproteins are primary targets of the immune system, which results in increased selection